08

2026

-

06

Hubei Guangchen Pharmaceutical Co., Ltd. has been awarded the Data Management Capability Maturity Level 2 certification.

Author:

Recently, Hubei Guangchen Pharmaceutical Co., Ltd. successfully obtained Level 2 (Managed) certification under the Data Management Capability Maturity Model (DCMM), signifying that the company has established a standardized data management system and possesses foundational data management capabilities. Moving forward, the company will deepen the integration of data with business functions such as quality control, production management, safety management, human resources, and corporate decision-making, thereby providing robust data support for the enterprise’s sustained, high-quality development.

Recently, Hubei Guangchen Pharmaceutical Co., Ltd. successfully obtained Level 2 (Managed) certification under the Data Management Capability Maturity Model (DCMM), signifying that the company has established a standardized data management system and possesses fundamental data management capabilities. Moving forward, the company will deepen the integration of data with business functions such as quality control, production management, safety management, human resources, and corporate decision-making, thereby providing robust data support for the enterprise’s sustained, high-quality development.

Related News

Hubei Guangchen Pharmaceutical Co., Ltd. has been awarded the Data Management Capability Maturity Level 2 certification.

Hubei Guangchen Pharmaceutical Co., Ltd. has been awarded the Data Management Capability Maturity Level 2 certification.

2026-06-08

Recently, Hubei Guangchen Pharmaceutical Co., Ltd. successfully obtained Level 2 (Managed) certification under the Data Management Capability Maturity Model (DCMM), signifying that the company has established a standardized data management system and possesses foundational data management capabilities. Moving forward, the company will deepen the integration of data with business functions such as quality control, production management, safety management, human resources, and corporate decision-making, thereby providing robust data support for the enterprise’s sustained, high-quality development.

Hubei Guangchen Pharmaceutical Co., Ltd. Held a Grand 2025 Work Summary Conference

Hubei Guangchen Pharmaceutical Co., Ltd. Held a Grand 2025 Work Summary Conference

2026-01-20

On January 18, 2026, Comrade Chen Shaoyan, General Manager of the company, chaired the 2025 Work Summary Meeting of Hubei Guangchen Pharmaceutical Co., Ltd. in the company’s second-floor conference room. The meeting was attended by the company’s shareholders and management personnel at or above the department head level. During the meeting, heads of various departments gave a comprehensive summary of their respective departments’ achievements in 2025, identified existing problems, and proposed improvement measures. General Manager Comrade Chen Shaoyan then laid out the company’s key tasks for 2026 in detail.

Breaking into the billion-dollar diabetes market! Hubei Guangchen secures the first generic version of linagliptin-metformin extended-release tablets.

Breaking into the billion-dollar diabetes market! Hubei Guangchen secures the first generic version of linagliptin-metformin extended-release tablets.

2025-11-01

On October 28, 2025, according to an announcement on the official website of the NMPA, the Lixagliptin-Metformin Extended-Release Tablets submitted by Hubei Guangchen Pharmaceutical Co., Ltd. have been approved for marketing (Approval Number: National Drug Approval No. H20255813), making it the first generic version of this dosage form in China. This approval fills a significant gap in the Chinese market for this extended-release formulation and is expected to provide type 2 diabetes patients with a more convenient medication option.

Hubei Guangchen Pharmaceutical Co., Ltd. held a 2025 first-half work summary meeting

Hubei Guangchen Pharmaceutical Co., Ltd. held a 2025 first-half work summary meeting

2025-07-25

On July 25, 2025, Hubei Guangchen Pharmaceutical Co., Ltd. held a 2025 first-half work summary meeting. The meeting was presided over by General Manager Chen Shaoyan, and all members of the company's board of directors and managers at the director level and above attended the meeting. Team leaders were also in attendance.